Ascendis Pharma A/S (ASND) Downgraded to Hold at Zacks Investment Research
According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “
Other analysts have also issued reports about the stock. Leerink Swann reaffirmed a buy rating on shares of Ascendis Pharma A/S in a research report on Friday, September 2nd. TheStreet raised shares of Ascendis Pharma A/S from a sell rating to a hold rating in a research report on Tuesday, September 6th. Finally, Wedbush initiated coverage on shares of Ascendis Pharma A/S in a research report on Monday, September 26th. They set an outperform rating and a $34.00 price target on the stock.
Shares of Ascendis Pharma A/S (NASDAQ:ASND) opened at 20.02 on Monday. The stock’s 50 day moving average is $19.46 and its 200 day moving average is $16.20. Ascendis Pharma A/S has a 12 month low of $11.92 and a 12 month high of $21.70. The firm’s market capitalization is $504.36 million.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, August 31st. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.10. Ascendis Pharma A/S had a negative net margin of 818.32% and a negative return on equity of 47.61%. Equities research analysts forecast that Ascendis Pharma A/S will post ($3.14) earnings per share for the current fiscal year.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.